Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL - Episode 3
CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection
Experts discuss sequencing treatments in the third-line setting or beyond for patients who have not received chimeric antigen receptor T-cell therapy (CAR T) previously, comparing bispecific antibodies, CAR T, and other agents like polatuzumab and tafasitamab, while also considering patient factors and disease characteristics when selecting among available CAR-T options (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], and tisagenlecleucel [tisa-cel]).
Video Player is loading.
Video content above is prompted by the following:
- In the third-line setting or beyond, for those who did not receive CAR T previously, how are you sequencing among bispecific antibodies, CAR T, and other available agents (eg, polatuzumab, tafasitamab)?
- What patient factors or disease characteristics do you take into account when choosing among the available CAR T-cell therapy options (axi-cel, liso-cel, tisa-cel?
Related Content:
